With the recent report that FMT from healthy donors halts the progression of new-onset type 1 diabetes in humans (47), our results suggest that the use of IL-2–tuned FMT or of FMT enriched in specific taxa could represent an improved treatment modality. Here, IL2 is linked to type 1 diabetes mellitus.